CrossRef Nutriomics and artificial intelligence nutrition obesity cohort (NAINOC): a design paper for a prospective cohort for nutrition and obesity research Minyoung Lee, Sungha Park, Soo-Hyun Park, Ho-Young Park, Yu Ra Lee, Min-Sun Kim, Miso Nam, Jangho Lee, Hyein Seo, Yong-ho Lee, Chan Joo Lee, Jae-Ho Park, Hye Hyun Yoo, Hyun-Jin Kim, Kyong-Oh Shin, Yoshikazu Uchida, Kyungho Park Clinical Hypertension.2025;[Epub] CrossRef Microvascular Outcomes of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes: A Systematic Review of Retinopathy and Nephropathy Evidence Atia Arif, Sanu Lama, Bhavna Singla, Shivam Singla, Sunita Kumawat, Anusha Tharwani, Muhammad Usman, Hamna Khalid, Venkata Madusudana Rao Kanukollu, Osatohanmwen Ekomwereren, Shabir Khan Cureus.2025;[Epub] CrossRef Integrating UHPLC-QE-MS and Bioinformatics with Experimental Validation Reveals MAPK/FOS-Mediated Podocyte Apoptosis as the Key Mechanism of Alpiniae oxyphyllae and Saposhnikovia divaricata in Treating Diabetic Kidney Disease Xian Wang, Lin Zhang, Rongxin Tang, Wenlong Zhang, Yiqiang Xie, Kai Li Pharmaceuticals.2025
Testing for markers like GLP1R rs6923761 and GIPR rs1800437 helps determine whether semaglutide, tirzepatide, or microdose protocols will work best for your biology
The big takeaway is that semaglutides heart benefits are real but the decision to use it should involve a discussion of tolerability, costs, and individual health risks
Mesotherapy (Lipodissolve) for fat reduction
The timeline follows a predictable pattern based on clinical trial data and the pharmacology of incretin-based therapies
Supervision involves more than writing a prescription
